Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.

@article{Bennett2010TreatmentOS,
  title={Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.},
  author={Michael Bennett and Geraldine P Schechter},
  journal={Seminars in hematology},
  year={2010},
  volume={47 2},
  pages={143-7}
}
Splenic marginal zone lymphoma (SMZL) is an uncommon indolent B-cell lymphoma causing marked splenic enlargement with CD20-rich lymphoma cells infiltrating blood and bone marrow. In the pre-rituximab era, the treatment of choice for patients with symptomatic splenomegaly or threatening cytopenia was splenectomy, since chemotherapy had limited efficacy. Responses to splenectomy occurred in approximately 90% of patients. However, SMZL patients are often elderly and poor surgical risks. Since… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…